BeiGene (BGNE)
(Delayed Data from NSDQ)
$246.04 USD
+12.40 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $246.27 +0.23 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$246.04 USD
+12.40 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $246.27 +0.23 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill
AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AMAG disappoints investors with earnings and sales miss in the third quarter.
4 Stocks to Buy From Sectors With Maximum Job Gains
by Zacks Equity Research
The American jobs' market added new positions in October at a better-than-expected pace. Here's how to make the most of it.
Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance
by Zacks Equity Research
Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.
BeiGene, Ltd. (BGNE) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Reata Successfully Completes Neuromuscular Disorder Study
by Zacks Equity Research
Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.
BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.
Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View
by Zacks Equity Research
Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.
Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.
AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.
Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.
PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies
by Zacks Equity Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.
Why Earnings Season Could Be Great for BeiGene (BGNE)
by Zacks Equity Research
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
Can Pharmacy Services Drive CVS Health's (CVS) Q2 Earnings?
by Zacks Equity Research
Akin to the previous quarters, net new business and the steady uptake of Maintenance Choice programs are likely to bolster CVS Health's (CVS) PBM business in Q2.
Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018
by Zacks Equity Research
Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Intrexon (XON) incurs narrower-than-expected loss in the fourth quarter of 2018.
Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat
by Zacks Equity Research
Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.
BeiGene, Ltd. (BGNE) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BeiGene, Ltd. (BGNE) Is Up 12.82% in One Week: What You Should Know
by Zacks Equity Research
Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can The Uptrend Continue for BeiGene (BGNE)?
by Zacks Equity Research
Investors certainly have to be happy with BeiGene, Ltd. (BGNE) and its short term performance.
Earnings Estimates Moving Higher for BeiGene (BGNE): Time to Buy?
by Zacks Equity Research
BeiGene (BGNE) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
BeiGene (BGNE) Catches Eye: Stock Jumps 8.3%
by Zacks Equity Research
BeiGene (BGNE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
BeiGene (BGNE): Moving Average Crossover Alert
by Zacks Equity Research
BeiGene, Ltd. (BGNE) could be a stock to avoid from a technical perspective